Next Article in Journal
Detecting Retroviral Sequences in Chronic Fatigue Syndrome
Next Article in Special Issue
Development of ST-246® for Treatment of Poxvirus Infections
Previous Article in Journal
Poxvirus Exploitation of the Ubiquitin-Proteasome System
Previous Article in Special Issue
Synthesis and Early Development of Hexadecyloxypropyl-cidofovir: An Oral Antipoxvirus Nucleoside Phosphonate
Article Menu

Article Versions

Export Article

Open AccessReview
Viruses 2010, 2(10), 2381-2403; doi:10.3390/v2102381

Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections

1
Division of Infectious Diseases, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
2
Infectious Diseases Section, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
*
Author to whom correspondence should be addressed.
Received: 19 September 2010 / Revised: 9 October 2010 / Accepted: 13 October 2010 / Published: 20 October 2010
(This article belongs to the Special Issue Antivirals Against Poxviruses)
Download PDF [101 KB, uploaded 12 May 2015]

Abstract

Despite the eradication of smallpox several decades ago, variola and monkeypox viruses still have the potential to become significant threats to public health. The current licensed live vaccinia virus-based smallpox vaccine is extremely effective as a prophylactic vaccine to prevent orthopoxvirus infections, but because of safety issues, it is no longer given as a routine vaccine to the general population. In the event of serious human orthopoxvirus infections, it is important to have treatments available for individual patients as well as their close contacts. The smallpox vaccine and vaccinia immune globulin (VIG) were used in the past as therapeutics for patients exposed to smallpox. VIG was also used in patients who were at high risk of developing complications from smallpox vaccination. Thus post-exposure vaccination and VIG treatments may again become important therapeutic modalities. This paper summarizes some of the historic use of the smallpox vaccine and immunoglobulins in the post-exposure setting in humans and reviews in detail the newer animal studies that address the use of therapeutic vaccines and immunoglobulins in orthopoxvirus infections as well as the development of new therapeutic monoclonal antibodies.
Keywords: orthopoxvirus; variola virus; vaccinia virus; monkeypox virus; post-exposure vaccination; Dryvax; Lister; modified vaccinia Ankara (MVA); vaccinia immune globulin (VIG); monoclonal antibodies orthopoxvirus; variola virus; vaccinia virus; monkeypox virus; post-exposure vaccination; Dryvax; Lister; modified vaccinia Ankara (MVA); vaccinia immune globulin (VIG); monoclonal antibodies
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Xiao, Y.; Isaacs, S.N. Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections. Viruses 2010, 2, 2381-2403.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top